Press Releases
Page 5 • 12 itemsAccess critical pharma & biotech press releases. Stay ahead on drug approvals, clinical trials, M&A, and regulatory updates impacting global markets.
Silexion Therapeutics Submits Phase 2/3 Trial Application for SIL204 KRAS-Targeted Pancreatic Cancer Treatment
Silexion Therapeutics successfully submits Phase 2/3 clinical trial application to Germany's BfArM for SIL204, targeting KRAS-driven pancreatic cancer.
Novo Nordisk Presents New Wegovy Data for Women with Obesity at European Congress on Obesity 2026
Novo Nordisk unveils new clinical data on Wegovy for women with obesity and next-generation weight loss treatments at European Congress on Obesity in Istanbul.
Solid Biosciences Receives European Orphan Drug Designation for SGT-003 Duchenne Muscular Dystrophy Treatment
Solid Biosciences secures European Commission orphan drug designation for SGT-003, advancing gene therapy development for Duchenne muscular dystrophy patients.
Cytokinetics MYQORZO (Aficamten) Takes Center Stage at European Society of Cardiology Heart Failure 2026 Congress
Cytokinetics presents nine studies on MYQORZO (aficamten) at ESC Heart Failure 2026, including late-breaking science on the newly approved oHCM treatment.
Artiva Biotherapeutics' AlloNK Receives FDA Fast Track Designation for Refractory Rheumatoid Arthritis Treatment
FDA grants Fast Track Designation to Artiva's AlloNK (AB-101) for refractory rheumatoid arthritis, accelerating development of innovative NK cell therapy.
SQ Innovation's Lasix ONYU Receives CE Marking Approval, Advances Toward European Market Authorization
SQ Innovation announces CE marking for Lasix ONYU medical device under EU MDR, plus EMA centralized procedure eligibility for European market expansion.
Elanco's Negasunt and Tanidil Receive FDA Emergency Authorization for New World Screwworm Treatment in Livestock
FDA grants emergency use authorization for Elanco's Negasunt Powder and Tanidil to combat New World screwworm in livestock, preparing U.S. veterinarians.
Opella's Essentiale Shows 2.5x Greater Liver Fat Reduction in Breakthrough EXCEL Trial for Fatty Liver Disease
Opella's Essentiale essential phospholipids demonstrated 2.5 times greater liver fat reduction vs diet/exercise alone in MASLD patients in EXCEL trial.
Advanced Bifurcation Systems Acquires Svelte Medical Systems in Major Coronary Stent Deal
Advanced Bifurcation Systems Inc. acquires Svelte Medical Systems, expanding its coronary angioplasty portfolio with drug-eluting stents and regulatory approvals.
Zentiva Appeals EU Court Decision on Urban Wastewater Directive Affecting Generic Medicine Access
Zentiva and generic drugmakers challenge EU Urban Wastewater Directive at CJEU, citing concerns over patient access and medicine affordability in Europe.
AB Science Secures Loan Repayment Deferrals to Fund R&D Operations Through 2028
AB Science reaches agreement with creditors for 2-year state loan deferral and 12-month EIB credit extension, redirecting savings to R&D investments.
Mundipharma's REZZAYO (Rezafungin) Meets Primary Endpoint in Phase III ReSPECT Trial for Fungal Disease Prevention
Mundipharma announces positive Phase III ReSPECT trial results for REZZAYO (rezafungin) in preventing invasive fungal diseases in stem cell transplant patients.